Protalix Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Carmiel Israel (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2005
NCT00258778
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Protalix | Protalix Biotherapeutics | Protalix Inc. | Protalix Ltd | Protalix Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

taliglucerase alfa (elelyso) (7 trials)

Drugs in Phase 3 Trials (3)

agalsidase alfa (Replagal) (1 trial)

agalsidase beta (Fabrazyme) (1 trial)

pegunigalsidase alfa (Elfabrio) (10 trials)

Drugs in Phase 2 Trials (3)

dnase (2 trials)

oprx-106 (2 trials)

prx-112 (2 trials)

Drugs in Phase 1 Trials (3)

alglucerase (ceredase) (1 trial)

prx-105 (1 trial)

prx-115 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Cystic Fibrosis (Phase 2)

Fabry Disease (Phase 3)

Fibrosis (Phase 2)

Gaucher Disease (Phase 4)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 10